brain tumor
Conditions
Interventions
Remimazolam with flumazenil antagonization is administered in anesthetic management of awake craniotomy
Propofol is administered in anesthetic management fo awake craniotomy
Sponsors
Sapporo Medical University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient aged more than 65 years old age Patient who undergo elective awake craniotomy using asleep-awake-asleep technique Patient whose preoperative physical status is good (ASA-PS 1-3)
Exclusion criteria
Exclusion criteria: Patient who has allergy for propofol, remimazolam and flumazenil Patient who has severe hepatic and/or renal dynfunction Patient who determined as inappropriate for enrollment by the researcher of this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time required for emergence from anesthesia | — |
Secondary
| Measure | Time frame |
|---|---|
| Time required for extubation Time course of sedative score Serum concentration of remimazolam and propofol Blood pressure, heart rate and SpO2 during general anesthesia Incidence of awake craniotomy failure Dose of flumazenil Incidence of unintended re-sedation during awake phase Dose required for re-anesthesia induction Time required for re-anesthesia induction Time required for re-emergence Incidence of nausea and vomiting during awake phase | — |
Countries
Japan
Contacts
Public ContactTomohiro Chaki
Sapporo Medical University School of Medicine Department of Anesthesiology
Outcome results
None listed